AzTrials
AzTrials

Breast CancerPhase 1VascuLens RCTNCT07080463

Application of VascuLens 2.0, A Mixed Reality System for Surgical Guidance During DIEP Flap Harvest

A Phase 1 study testing vasculens and cta in people with Breast Cancer, run by University of British Columbia at 1 site in Canada.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

This study incorporates the use of the VascuLens system, which relies on a mixed reality headset and software system, during the pre-operative stage of DIEP flap surgery. VascuLens utilizes augmented reality (AR) technology to project vasculature images obtained from computed tomography angiography (CTA) onto the… Read more about this study

Who is it for?
Ages 19 years and older, women only
Conditions the study is for
Breast Cancer
What is being tested?
vasculens and cta
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteCanada
Study dates
1 May 2025to 1 May 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients must be ≥ 19 years old
  • Patients must be undergoing a DIEP flap surgery after mastectomy for breast cancer or risk reduction
  • Patient is already scheduled for a pre-operative CTA as part of routine standard of care.
  • Note: Non-English speaking participants will be given the option to have a translator.

Who cannot join

  • Patients who have had a prior DIEP flap, as they may not have standard vascular anatomy and the previous surgery may have resulted in scarring and fibrosis that would potentially interfere with the accuracy of the projected anatomical information.
  • Patients who have not had a pre-operative CTA because no imaging-based surgical guidance can be provided
  • Patients who are pregnant at the time of surgery
  • Patients who had a pre-operative CTA done before they were considered for this trial

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Canada1 site
  • UBC Breast Reconstruction Research Lab

    Vancouver, British Columbia, V6T 2B5

Other trials in Canada

About this study

Official title: Application of VascuLens 2.0, A Mixed Reality System for Surgical Guidance During DIEP Flap Harvest: A Randomized Controlled Trial

This study incorporates the use of the VascuLens system, which relies on a mixed reality headset and software system, during the pre-operative stage of DIEP flap surgery. VascuLens utilizes augmented reality (AR) technology to project vasculature images obtained from computed tomography angiography (CTA) onto the patient's body. These projections are then traced onto the patient, and the accuracy of the key vascular anatomical landmarks in the projected images is compared to the accuracy of the conventional surgical markings of the same anatomical landmarks against the actual location of the dissected blood vessels. Higher accuracy may lead to improved patient care, reduced operative time and reduced risk of complications.

Read the detailed description

Background and Rationale:

Breast reconstruction surgery is a surgical procedure that can be done after a breast removal surgery ("mastectomy"). One of the more common surgical methods for reconstruction involves taking a section of tissue from the abdomen that includes skin, fat, and blood vessels and relocating it to form the breast mound. This specific surgical method uses a section of the abdomen called the Deep Inferior Epigastric Artery Perforator (DIEP) flap. In order to accurately identify the necessary blood vessels for this surgery, surgeons generally take CTA (computed tomography angiography, a type of medical imaging to visualize a patient's blood vessels and tissues) of the abdomen before surgery to map out and visualize the positions of all the blood vessels during surgery.

The VascuLens is a mixed reality system that projects anatomical information onto a patient. In this study, the Vasculens system will project anatomical information, derived from the computed tomography angiography (CTA) images taken before surgery, onto a patient's body just prior to surgery.

In turn, the relevant projected vascular anatomy will be drawn onto the patient with a permanent marker. This will allow surgeons to see where important blood vessels are throughout the entire surgery rather than visualizing them in their minds. Great care, and a significant amount of time in the 8-hour DIEP flap reconstruction surgery, is often dedicated to separating the perforator arteries of the deep inferior epigastric artery and vein surrounding the rectus abdominis muscle. The authors of this study have developed the Vasculens system because they believe it will reduce the time to dissect the perforator arteries. Our pilot work confirmed the feasibility of use of the Vasculens system to accurately project patient-specific segmented anatomy for a DIEP free flap surgery.

Purpose:

The purpose of this study is to determine operative times with the use of the VascuLens system in comparison to the standard use of CTA in breast reconstruction with a DIEP flap. The standard of care for DIEP flap reconstruction is to obtain a preoperative CTA of the abdomen. These CTA images are reviewed pre-operatively and anatomic information is marked onto the patient using a ruler and marker for surgical planning. These are the standard surgical markings. In this study intervention, by using VascuLens, the CTA images and anatomic information will be projected onto the patient and traced onto the patient using a marker for surgical planning. The difference in standard of care is the additional visualization of the anatomic information being projected with use of VascuLens.

Objectives:

Primary Aims -To determine if use of the VascuLens system, a software using a mixed reality headset, reduces operative time for DIEP flap reconstruction surgery.

Secondary Aims

  • To determine if use of the VascuLens system reduces surgical complications following DIEP flap reconstruction surgery.
  • To determine if use of the VascuLens system reduces operative time variability for DIEP flap reconstruction surgery

Hypothesis:

Use of the VascuLens system reduces operative time and complications.

Study Design:

This is a randomized controlled trial with two parallel groups.The group allocation ratio for each study arm is 1:1.

  • Group 1 (Control): Standard of care with DIEP flap harvest informed by CTA imaging only.
  • Group 2 (Intervention): Standard of care with DIEP flap harvest informed by CTA imaging + VascuLens system.

This study occurs during all clinical visits which are part of standard of care, so no additional visits are required. The procedure occurs during the pre-operative and operative procedure and takes approximately 10 to 15 minutes during each stage.

Data Collection and Measures

There are TWO components to this study:

  1. Operative times
  2. Chart review of surgical complications
  3. Operative Times

Operative times of the DIEP flap harvest will be collected by a research team member. Time points collected will be:

  • Start of procedure, as determined by initial skin incision
  • Identification of first perforator.
  • perforator dissection.
  • pedicle dissection.
  • Flap harvest completion.
  • The time from skin incision to completion of flap harvest will be the total procedure time.
  1. Surgical Complications
  • Will be measured by abdominal bulge/hernia [Yes or No] recorded at 6 months, need to return to operating room and indication [yes or no, indications include arterial compromise, venous compromise, pedicle distortion, hematoma, thrombus], flap loss [Yes or No, partial or full], abdominal dehiscence, perforator injury, all recorded at 1 month post-operation. The chart review of this data will be collected by a research team member through participants' chart and EMR.

Additional data variables collected for assessment of potential confounders includes:

  • Patient characteristics (BMI, age, surgical indication (immediate reconstruction, delayed reconstruction, delayed immediate reconstruction)
  • Flap characteristics (number of perforators in harvested flap, flap volume)

Data Analysis:

Descriptive Statistics will be employed to present baseline patient characteristics (age, BMI, comorbidities) for both groups using means (SD) for continuous variables and frequencies (percentages) for categorical variables. Surgical Time will also be presented with descriptive statistics (mean, standard deviation, median, interquartile range) for surgical time in both groups.

Comparison of the primary outcome of surgical times will be completed by two-sample t-test (if the data is normally distributed) or Mann-Whitney U test (if data is non-normally distributed) for comparing the surgical times between the two groups. Normality of surgical times will be completed using the Shapiro-Wilk test. If the assumption of normality is violated, non-parametric tests will be selected. The effect size (Cohen's d) will be reported to quantify the magnitude of the difference in surgical times between the two groups.

Subgroup Analyses will be conducted based on factors including surgeon performing procedure, complexity of the surgery (number of perforators), and patient characteristics (BMI and flap volume).

For comparison of secondary outcomes, including complication rates, chi-squared test will be employed for categorical outcomes.

Conditions
Breast Cancer
Being tested
vasculens and cta
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • vasculens and ctaProcedure or surgery

    using vasculens and cta for one group and cta for the second group (control)

Study groups in NCT07080463
Study groupRoleWhat they receive
not using vasculensNo interventionNot described
using vasculensExperimentalNot described
Receives: Procedure: vasculens and cta

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Operative times

    Measured: surgery time

Secondary outcomes (1)
  1. Chart review of surgical complications

    Measured: at 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jul 2025
  2. Study start1 May 2025
  3. Primary completion1 May 2027 (estimated)
  4. Study completion1 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07080463
Sponsor's protocol ID
H24-02372
Acronym
VascuLens RCT
Status last verified
Jul 2025
First submitted
14 Jul 2025
Last updated
10 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing vasculens and cta in people with Breast Cancer, run by University of British Columbia at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 10 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Operative times (time frame: surgery time). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in